IDHIFA — FDA application NDA209606
Listed sponsor: BRISTOL MYERS SQUIBB · BMY company profile · exact_unique
Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.
FDA application facts
| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
|---|---|---|---|---|---|---|---|---|
| 001 | IDHIFA | ENASIDENIB MESYLATE | TABLET | ORAL | EQ 50MG BASE | Prescription | not listed | Yes |
| 002 | IDHIFA | ENASIDENIB MESYLATE | TABLET | ORAL | EQ 100MG BASE | Prescription | not listed | Yes |
Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.
Orange Book patent and exclusivity listings
| Listing | Product | Descriptive date | Flags/code |
|---|---|---|---|
| Patent 10610125 | 001 | listed patent expiry date: 2030-06-21 | U-2087 |
| Patent 10610125 | 002 | listed patent expiry date: 2030-06-21 | U-2087 |
| Patent 10294215 | 001 | listed patent expiry date: 2033-01-07 | drug product, U-2087 |
| Patent 10294215 | 002 | listed patent expiry date: 2033-01-07 | drug product, U-2087 |
| Patent 9512107 | 001 | listed patent expiry date: 2033-01-07 | drug substance, drug product, U-2087 |
| Patent 9512107 | 002 | listed patent expiry date: 2033-01-07 | drug substance, drug product, U-2087 |
| Patent 10093654 | 001 | listed patent expiry date: 2034-08-01 | drug substance, drug product, U-2087 |
| Patent 10093654 | 002 | listed patent expiry date: 2034-08-01 | drug substance, drug product, U-2087 |
| Patent 9738625 | 001 | listed patent expiry date: 2034-08-01 | drug substance |
| Patent 9738625 | 002 | listed patent expiry date: 2034-08-01 | drug substance |
| Patent 9732062 | 001 | listed patent expiry date: 2034-09-16 | drug substance |
| Patent 9732062 | 002 | listed patent expiry date: 2034-09-16 | drug substance |
Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.
Compound cross-links
- ENASIDENIB MESYLATE · UNII UF6PC17XAV · lmmol compound ORZHZQZYWXEDDL-UHFFFAOYSA-N · CHEMBL3989931
Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.
Related pages
Sponsor company · FDA-approved application index
Peer clusters: Large-cap biopharma
Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.
Regulatory listing data as published by FDA; not medical or investment advice.